HLB bioStep Co.,Ltd. (KOSDAQ:278650)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,420.00
0.00 (0.00%)
At close: Sep 3, 2026

HLB bioStep Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
72,15174,05058,16952,81486,27764,403
Other Revenue
-----0
72,15174,05058,16952,81486,27764,403
Revenue Growth
9.27%27.30%10.14%-38.78%33.96%10.05%
Cost of Revenue
18,97218,14317,33917,53332,34323,147
Gross Profit
53,17855,90740,83035,28153,93441,256
Selling, General & Admin
53,56657,70946,40731,62340,98626,527
Research & Development
872.41936.39824.35811.99978.141,165
Amortization of Goodwill & Intangibles
692.45692.1492.5263.2870.2830
Other Operating Expenses
460.09889.67858.76712.99709.09696.32
Operating Expenses
59,46664,54653,87736,46748,62532,249
Operating Income
-6,288-8,639-13,048-1,1865,3099,007
Interest Expense
-2,051-2,051-858.96-3,471-4,246-184.7
Interest & Investment Income
817.3817.31,8211,4691,40185
Earnings From Equity Investments
-4,516-4,4601.68-488.74-1,6593,608
Currency Exchange Gain (Loss)
-10.3-10.34.1632.313.819.9
Other Non Operating Income (Expenses)
-1,54933.86233.81561.71-2,767775.48
EBT Excluding Unusual Items
-13,597-14,309-11,845-3,083-1,94713,300
Gain (Loss) on Sale of Investments
1,7141,714182.733,418534.22-440.56
Gain (Loss) on Sale of Assets
16.3516.35135.08-9.47-23.37-33.11
Asset Writedown
-4,948-4,948---907.99-
Pretax Income
-16,814-17,527-11,528325.66-2,34512,827
Income Tax Expense
2,5892,728-1,835379.9-1,4621,295
Earnings From Continuing Operations
-19,403-20,255-9,693-54.24-882.7311,532
Net Income to Company
-19,403-20,255-9,693-54.24-882.7311,532
Minority Interest in Earnings
975.091,2931,128-109.81-125.27-501.4
Net Income
-18,428-18,962-8,564-164.04-1,00811,031
Net Income to Common
-18,428-18,962-8,564-164.04-1,00811,031
Net Income Growth
-----32.87%
Shares Outstanding (Basic)
171717151414
Shares Outstanding (Diluted)
171717151414
Shares Change
-1.54%0.72%9.40%9.59%0.02%1.35%
EPS (Basic)
-1114.34-1121.56-510.23-10.69-72.00809.35
EPS (Diluted)
-1114.34-1121.56-510.23-10.69-72.00790.00
EPS Growth
-----31.42%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-2,5171,113-20,5941,1891,587-11,135
Free Cash Flow Per Share
-152.2165.84-1226.9077.53113.33-795.47
Gross Margin
73.70%75.50%70.19%66.80%62.51%64.06%
Operating Margin
-8.71%-11.67%-22.43%-2.25%6.15%13.98%
Profit Margin
-25.54%-25.61%-14.72%-0.31%-1.17%17.13%
Free Cash Flow Margin
-3.49%1.50%-35.40%2.25%1.84%-17.29%
EBITDA
-1,478-3,908-8,3452,2909,41212,033
EBITDA Margin
-2.05%-5.28%-14.35%4.33%10.91%18.68%
D&A For EBITDA
4,8104,7314,7033,4764,1033,026
EBIT
-6,288-8,639-13,048-1,1865,3099,007
EBIT Margin
-8.71%-11.67%-22.43%-2.25%6.15%13.98%
Effective Tax Rate
---116.66%-10.09%
Advertising Expenses
-91.38178.58152.13340.63256.01